3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Opportunistic Infections
1
Inflammation
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Acquired Immunodeficiency Syndrome
1
Interventions
Omeprazole
2
soybean oil, phospholipid emulsion
1
dolutegravir
1
Vitamin D
1
Tumor Necrosis Factors
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Sufentanil
1
Sodium Chloride
1
Ritonavir
1
Riluzole
1
Oxycodone
1
Nutrition Assessment
1
Nucleosides
1
Naproxen
1
Infliximab
1
Fish Oils
1
Febuxostat
1
Exercise
1
Diet
1
Dexlansoprazole
1
Darunavir
1
Colchicine
1
Clindamycin
1
ClinOleic
1
Cephalexin
1
Anti-Bacterial Agents
1
Allopurinol
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Inflammation
×
Darunavir
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn